Africa: After Centuries, TB Is Still the Bridesmaid, Never the Bride

Despite being one of humanity's oldest diseases, tuberculosis continues to operate in the margins of global health policy and investment, even as it claims nearly 1.3 million lives annually across Africa and Asia. This paradox—persistent devastation alongside chronic underfunding—represents a significant blind spot for European investors seeking sustainable, high-impact opportunities in African healthcare markets. The tuberculosis crisis in Africa defies conventional logic. Unlike the celebrity status afforded to HIV/AIDS or the recent pandemic urgency surrounding COVID-19, TB remains systemically neglected despite its staggering burden. Sub-Saharan Africa accounts for approximately 23% of global TB cases, with mortality rates concentrated among vulnerable populations including the poor, immunocompromised, and those in conflict-affected regions. Yet TB investment trails competitors by orders of magnitude: while global TB research and development receives roughly $2 billion annually, this pales against the $10-15 billion mobilized for vaccine development in response to newer threats. This funding disparity creates a peculiar market inefficiency. The World Health Organization estimates a $16.5 billion annual funding gap in TB prevention, diagnosis, and treatment across low- and middle-income countries. For European medical device manufacturers, diagnostic companies, and pharmaceutical innovators, this represents not merely a humanitarian crisis but a severely underserved commercial market with structural